title: Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy.
abstract: BACKGROUND
  Oxidative stress could play a role in pathogenesis of hepatitis C virus (HCV) infection. The aim of our study is to determine oxidant/antioxidant status of patients with chronic hepatitis C (CHC), and the effect of pegylated interferon alfa-2b plus ribavirin combination therapy on oxidative stress.
  
  
  METHODS
  Nineteen patients with chronic HCV infection and 28 healthy controls were included in the study. In control and patient groups, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, erythrocyte malondialdehyde (MDA) levels, erythrocyte CuZn-superoxide dismutase (SOD), erythrocyte glutathione peroxidase (GSH-Px) activities were measured. After pegylated interferon alfa-2b and ribavirin combination therapy for 48 weeks, these parameters were measured again in the patient group.
  
  
  RESULTS
  Serum MDA levels increased significantly in CHC patients (n:19), before the treatment when compared with healthy subjects (n:28) 9.28 +/- 1.61, 4.20 +/- 1.47 nmol/ml, p < 0.001 respectively. MDA concentration decreased significantly (p < 0.001) after the treatment as well as ALT, AST activity, in erythrocytes of these patients. Average antioxidant enzymes (superoxide dismutase and glutathione peroxidase) were significantly lower in erythrocytes of patients with CHC before treatment compared with the control group (both, p < 0.001). Chronic Hepatitis C patients after pegylated interferon alfa-2b and ribavirin therapy showed values of SOD, GSH-Px were significantly higher than pretreatment levels (both, p < 0.001).
  
  
  CONCLUSIONS
  Our results show that patients with chronic HCV infection are under the influence of oxidative stress associated with lower levels of antioxidant enzymes. These impairments return to level of healthy controls after pegylated interferon alfa-2b plus ribavirin combination therapy of CHC patients. Although interferon and ribavirin are not antioxidants, their antiviral capacity might reduce viral load, and inflammation, and perhaps through this mechanism might reduce virus-induced oxidative stress.
authors.affiliation: Gülhane Military Medical Academy, Department of Infectious Diseases and Clinic Microbiology, 06018, Etlik, Ankara, Turkey. lgorenek@gata.edu.tr
authors.forename: Görenek
authors.initials: G
authors.lastname: Levent
authors.forename: Acar
authors.initials: A
authors.lastname: Ali
authors.forename: Aydin
authors.initials: A
authors.lastname: Ahmet
authors.forename: Eyigun Can
authors.initials: EC
authors.lastname: Polat
authors.forename: Cetinkaya
authors.initials: C
authors.lastname: Aytaç
authors.forename: Eken
authors.initials: E
authors.lastname: Ayşe
authors.forename: Sayal
authors.initials: S
authors.lastname: Ahmet